DATE: September 13, 2017 
TIME:  9:00AM SGT 12:00PM AEDT

OR

DATE: September 12, 2017
TIME: 6:00PM PDT

To transform the promises of cell-based therapies into reality, a robust and scalable process is required to be compliant with cGMP regulations. From clinical to commercial manufacturing, processes need to produce progressively larger batches with consistent product quality. By accomplishing these processes, it can make affordable and sustainable therapies reach the market more quickly. Here we present a case study from the large scale development expansion of a process using human stem cells obtained from adult bone marrow.

Learning Objectives:

• An example of a process that was used to scale out an allogeneic cell therapy, based on a comprehensive look at a case study
• The advantage of using bioreactors for cell therapy manufacturing